Evidence map›Paper›PMID 29712619›Full record

ArticleeLife2018

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.

Jeroen Claus, Gargi Patel, Flavia Autore, Audrey Colomba, Gregory Weitsman, Tanya N Soliman, Selene Roberts, Laura C Zanetti-Domingues, Michael Hirsch, Francesca Collu and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 72 citations in OpenAlex.

  1. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  2. Modulating pseudokinase conformation from the ATP-binding site.Structure (London, England : 1993) · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Inhibition of mutationally activated HER2.Chemical biology & drug design · 2023
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Jeroen Claus *Protein Phosphorylation Laboratory, The Francis Crick Institute, London, United Kingdom.
Gargi Patel *Richard Dimbleby Department of Cancer Research, Randall Division and Division of Cancer Studies, Kings College London, London, United Kingdom.
Flavia AutoreRandall Division of Cell & Molecular Biophysics, Kings College London, London, United Kingdom.
Audrey ColombaProtein Phosphorylation Laboratory, The Francis Crick Institute, London, United Kingdom.
Gregory WeitsmanRichard Dimbleby Department of Cancer Research, Randall Division and Division of Cancer Studies, Kings College London, London, United Kingdom.
Tanya N SolimanProtein Phosphorylation Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID https://orcid.org/0000-0002-4687-629X
Selene RobertsCentral Laser Facility, Research Complex at Harwell, Science and Technology Facilities Council, Rutherford Appleton Laboratory, Didcot, United Kingdom.ORCID http://orcid.org/0000-0002-3732-0556
Laura C Zanetti-DominguesCentral Laser Facility, Research Complex at Harwell, Science and Technology Facilities Council, Rutherford Appleton Laboratory, Didcot, United Kingdom.
Michael HirschCentral Laser Facility, Research Complex at Harwell, Science and Technology Facilities Council, Rutherford Appleton Laboratory, Didcot, United Kingdom.
Francesca ColluRandall Division of Cell & Molecular Biophysics, Kings College London, London, United Kingdom.
Roger GeorgeThe Structural Biology Science Technology Platform, The Francis Crick Institute, London, United Kingdom.
Elena Ortiz-ZapaterDepartment of Asthma, Allergy and Respiratory Science, King's College London, Guy's Hospital, London, United Kingdom.
Paul R BarberRandall Division of Cell & Molecular Biophysics, Kings College London, London, United Kingdom.ORCID http://orcid.org/0000-0002-8595-1141
Boris VojnovicRandall Division of Cell & Molecular Biophysics, Kings College London, London, United Kingdom.
Yosef YardenDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Marisa L Martin-FernandezCentral Laser Facility, Research Complex at Harwell, Science and Technology Facilities Council, Rutherford Appleton Laboratory, Didcot, United Kingdom.
Angus CameronProtein Phosphorylation Laboratory, The Francis Crick Institute, London, United Kingdom.
Franca FraternaliRandall Division of Cell & Molecular Biophysics, Kings College London, London, United Kingdom.
Tony NgRichard Dimbleby Department of Cancer Research, Randall Division and Division of Cancer Studies, Kings College London, London, United Kingdom.
Peter J ParkerProtein Phosphorylation Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID http://orcid.org/0000-0002-6218-2933
King's College London · GBRutherford Appleton Laboratory · GBThe Francis Crick Institute · GBGuy's Hospital · GBQueen Mary University of London · GBWeizmann Institute of Science · IL

Funding

Biotechnology and Biological Sciences Research Council BB/G006911/1Biotechnology and Biological Sciences Research Council BB/G007160/1Biotechnology and Biological Sciences Research Council BB/H018409/1Cancer Research UK 15677Cancer Research UK 15683Cancer Research UK 16463Cancer Research UK C133/A1812Cancer Research UK C1519/A10331Cancer Research UK C1519/ A16463Cancer Research UK C1519/A6906Cancer Research UK Institute core fundingDepartment of Health C1519/ A16463Medical Research Council C1519/ A16463Medical Research Council MR/K015591/1Medical Research Council MR/L01257X/1
6 · The paper itself

Abstract

While targeted therapy against HER2 is an effective first-line treatment in HER2

Indexed as

Cell ProliferationProtein MultimerizationAdenosine TriphosphateBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansLapatinibNeuregulin-1PhosphorylationProtein ConformationProtein Kinase InhibitorsReceptor, ErbB-3Signal TransductionTumor Cells, CulturedAdenosine TriphosphateERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesERBB3 protein, humanLapatinibNeuregulin-1NRG1 protein, humanProtein Kinase InhibitorsReceptor, ErbB-3cancer biologycell biologyHER2HER3humankinase inhibitorslapatinibprotein kinasepseudokinase

Identifiers

PMID29712619
PMCPMC5929906
OpenAlexW2800602004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.